Hamartoma MRI

	Hamartoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hamartoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hamartoma MRI On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hamartoma MRI All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hamartoma MRI
CDC on Hamartoma MRI
Hamartoma MRI in the news
Blogs on Hamartoma MRI
Directions to Hospitals Treating Hamartoma
Risk calculators and risk factors for Hamartoma MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

On MRI, hamartoma is characterized by a heterogeneous signal in T1 and high signal due to fat and cartilaginous components in T2.^[1]

MRI is the modality of choice for assessment of hypothalamic, spleen, kidney, and other abdominal hamartomas.
T1: isointense to cerebral cortex
T1 C+ (Gd): no contrast enhancement
T2: iso to hyperintense to cerebral cortex, the higher the proportion of glial cells, the higher the T2 signal.
MR spectroscopy
- Reduced NAA/C
- Increased myoinositol
- Increased Cho/Cr compared to the amygdala has also been reported.